NOVO NORDISK A/S-B revenue breakdown overview

NOVO NORDISK A/S-B revenue for the last year amounted to 232.26 B DKK, the most of which — 215.10 B DKK — came from its highest performing source at the moment, Diabetes and Obesity Care, the year earlier bringing 156.41 B DKK. The greatest contribution to the revenue figure was made by United States — last year it brought NOVO NORDISK A/S-B 127.53 B DKK, and the year before that — 84.66 B DKK.